Resoundant’s Magnetic Resonance Elastography Accepted into FDA Biomarker Qualification Program as a Reasonably Likely Surrogate Endpoint in MASH Trials
Rochester, MN — December 16, 2025 — Resoundant, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Letter of Intent into the FDA’s Biomarker Qualification Program (BQP) for Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE) in clinical trials for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibros
12 minutes ago2 min read